Nivalis is laying off 80% of its staff including its CEO and CMO.

CV9014 failed a phase 2b trial in prostate cancer, but the company says its efficacy could be unlocked if used alongside checkpoint inhibitors.

Biogen’s new spinoff Bioverativ will be trading on the Nasdaq next from the start of month with two products, $325 million in the bank, hundreds of staffers…

Ionis, fresh from its approval of Spinraza with Biogen, says it is seeking to get its heart drug volanesorsen in front of the FDA as soon as possible, as it…

Fresh off its $5.2 billion deal for Ariad this week, Takeda shows no signs of slowing down in the deal stakes as it announces a collab and potentially a future…

After last year's decision to drop hereditary ATTR amyloidosis drug revusiran, Alnylam is planning to file new lead patisiran by year-end.

Daiichi Sankyo is to shutter its 170-person Indian R&D site in a bid to boost R&D productivity.

Pierre Fabre has struck a deal to develop dermatological formulations of Piqur Therapeutics’ PI3K/mTOR inhibitor PQR309.

Sarepta saw a 21% bump in its share price on Tuesday after it announced a new, early-stage research deal that could help treat all Duchenne muscular dystrophy…

R&D